Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
Latest From Pricing Debate
Interview: EULAR Head Counting The Cost Of Rheumatic Disease
Hans Bijlsma, president of the European League Against Rheumatism, tells Scrip about the progress being made in rheumatic and muskuloskeletal diseases, the areas where more innovation is needed and the importance of early treatment, both clinically and financially.
UK Industry Raises Conflict of Interest Concerns Over NICE’s PRIMA Service
PRIMA, the new service the National Institute for Health and Care Excellence offers to review economic models, must not be affected by confidentiality and conflict of interest issues, warns UK the pharmaceutical industry group, ABPI.
340B Legislative Reforms: Where Do We Go From Here?
Third US Senate committee hearing on 340B reforms focuses on the need for legislation requiring that providers report the drug discounts received and how they use the savings, but prospects for achieving change are unclear.
CREATES Act To Face Major Reshaping By Innovator-Friendly Amendments On Senate Floor
The Creating and Restoring Equal Access to Equivalent Samples Act clears US Senate Judiciary Committee. During markup, Sens. Hatch, R-Utah, and Cornyn, R-Tex., preview future amendments that would benefit innovators.
Congressional Action On Drug Pricing Blueprint Likely To Be Modest
Senate Health, Education, Labor and Pensions Committee Chair Lamar Alexander noted panel's lack of consensus on drug pricing policies advanced by the Trump Administration during June 12 hearing.
Shifting Medicare Part B Drugs To Part D: Legislative Prospects Cloudy
Democrats on US Senate Health Committee express concern that patient cost sharing could increase significantly with the change.
Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says
The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant
Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.